跳至主要内容
临床试验/NCT05740969
NCT05740969招募中2 期

Gene and Protein Expression Profiles After Treatment of Actinic Keratoses

Ismail Gögenur1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2023年2月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
48
试验地点
1
主要终点
Gene and protein expression profiles

研究概览

简要总结

The primary aim of this study is to investigate the effect of 5-fluorouracil, imiquimod, and melatonin for actinic keratosis on immunological gene, and protein expressions profiles. Secondarily, the aim is to assess the effect of the treatment on the histopathology of actinic keratoses.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participants should have a clinical diagnosis of actinic keratosis
  • Participants should be 18 years old or above
  • Participants must sign an informed consent

排除标准

  • Known allergic reaction to either 5-fluorouracil , imiquimod, or melatonin
  • Immunomodulating treatment
  • Predictable poor compliance (due to i.e. dementia, substance abuse, psychiatric disease, life-threatening disease or language barriers)
  • Pregnant or breastfeeding
  • Females not in menopause (defined as no menstruation during the last 12 months) should use a secure birth control (intrauterine devices, hormonal contraceptives including - oral pills, patches, vaginal rings and injections) during the entire period of the trial

研究组 & 干预措施

5-Fluorouracil

Active Comparator

Patients will be asked apply a 40 mg/g creme containing 5-Fluorouracil once a day on their lesion for 10 days. A biopsy will be taken four days after last application. The patient will be refered to a dermatologist for further treatment, if necessary.

干预措施: 5Fluorouracil (Drug)

Imiquimod

Active Comparator

Patients will be asked apply a 50 mg/g creme containing imiquimod thrice a week on their lesion for 10 days. A biopsy will be taken four days after last application. The patient will be refered to a dermatologist for further treatment, if necessary.

干预措施: Imiquimod (Drug)

Melatonin

Experimental

Patients will be asked apply a 25 mg/g creme containing melatonin once a day on their lesion for 10 days. A biopsy will be taken four days after last application. The patient will be refered to a dermatologist for further treatment, if necessary.

干预措施: Melatonin (Drug)

结局指标

主要结局

Gene and protein expression profiles

时间窗: 10 days of treatment

次要结局

  • histopathological assessment of actinic keratoses(10 days of treatment)

研究者

发起方
Ismail Gögenur
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Ismail Gögenur

Professor

Zealand University Hospital

研究点 (1)

Loading locations...

相似试验